Trial Profile
A phase II study of cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) in high-risk previously untreated patients with CLL [chronic lymphocytic leukaemia].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 10 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2011 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.